Silo Pharma Initiates Feasibility Study of SPC-15 Novel Intranasal Formulation for PTSD
Portfolio Pulse from Benzinga Newsdesk
Silo Pharma, Inc. (NASDAQ:SILO) has initiated a feasibility study for its intranasal therapeutic drug SPC-15, aimed at treating PTSD. The study will evaluate a selected delivery mechanism for the drug. The company's partner for the study is a developer and manufacturer of innovative drug delivery systems and technology.
September 12, 2023 | 12:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Silo Pharma has initiated a feasibility study for its PTSD therapeutic drug SPC-15. This could potentially lead to advancements in the company's product pipeline and may impact its stock positively in the short term.
The initiation of a feasibility study for a new drug indicates progress in Silo Pharma's product development. This could potentially lead to a new revenue stream for the company if the drug proves to be effective and gets approved. Therefore, this news is likely to have a positive impact on the company's stock in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100